The clinical profile for apomorphine sublingual (SL), a new centrally active agent for the management of the erectile dysfunction (ED) patient, is described in this article. Apomorphine SL is shown to be rapid in onset (71% of patients within 20 min) with a consistent, predictable response that is independent of severity (mild, moderate or severe), the underlying aetiology or the presence of significant co-morbidities (coronary artery disease, hypertension, etc). Importantly, there is also consistent long-term clinical benefit ( > 90% of attempts being successful over 18 months), for patients who respond to therapy and a benign side effect profile ( < 13.4% patients with adverse events). This formulation of apomorphine has a speed of onset and overall clinical profile that may offer particular advantages to the patient in terms of spontaneity and predictability of response. ED is a complex disease of varying aetiologies and severities often associated with a number of co-morbidities that require diverse solutions. Given the need for customisation of therapy to individual patient needs, the clinical profile of apomorphine SL would indicate that it will make a most welcome addition to the physician's armamentarium against ED.
Introduction
Penile erection is a complex series of integrated neural and vascular events culminating in the accumulation of blood under pressure in the penis that causes end-organ rigidity. It relies on the coordination of specific neural and humoral events at multiple levels of the neuroaxis. There is an absolute requirement for central neural input to ensure normal consensual sexual function and imbalance at any level can result in erectile dysfunction (ED). Intuitively and empirically appropriate erotic stimulation transfers into sexual action in a healthy man. The brain receives a variety of signals (tactile, olfactory, visual, imaginary, memory based, etc), 1 processes these and checks the appropriateness and the opportunity. 2 Subsequently, an integrated efferent response is initiated via the autonomic nervous system. The pathways involved are complex and thus, still relatively incompletely understood. 3 Perhaps not surprisingly therefore, the realisation of the clinical potential of centrally active drugs and their development have been relatively slow. However, the efficacy of sublingual (SL) apomorphine, first demonstrated to initiate erection in animals over 20 y ago, 3 has been shown unequivocally in man and represents the vanguard of an exciting new era in the use of central nervous system (CNS) drugs in the management of sexual problems.
If we assume that vascular problems are the predominant local aetiological factors in ED, it is logical to inquire why a centrally acting agent would be effective as therapy. As a consequence of activity in the CNS there is a secondary action on the peripheral vasculature that is hard wired. Thus the net result of a centrally acting drug for ED replicates much of the normal sexual signalling and in the periphery is to that extent equivalent to the action of a directly acting vascular agent. In essence all erectogenic agents produce localised vasodilation and clinical benefit relies on there being un-used vasodilator capacity in a man with ED. Potentially, this reserve of vascular function can be accessed either by enhancing it locally (eg, sildenafil 4 or phentolamine 5 ) or by driving the native signalling system (nerves) to deliver more signal to the periphery (the pudendal vasculature and penile cavernosal tissue). 6 It is pertinent to note, however, that within the autonomic nervous system there are counterbalancing vasoconstrictor pathways eg the sympathetic nervous system with inherently high intrinsic activity that may limit the effectiveness of any agent with an exclusive peripheral action. Ultimately, the overall balance within the autonomic nervous system is controlled by the CNS. Not only does central neural input control normal function but it also represents an attractive locus for rectification of any abnormal erectile function or ED. Drugs acting within the CNS are therefore capable, by re-dressing any imbalance and enhancing efferent transmission, of providing benefit to patients with ED arising from a wide range of aetiologies.
Apomorphine has completed development as an effective and rapid treatment for ED of varied aetiologies. The clinical profile results from an action primarily in the paraventricular nucleus of the hypothalamus. 7 At this locus, apomorphine acts as a selective dopaminergic agonist enhancing the natural erectile process and thereby helping to restore normal autonomic balance in the control of penile function. 8 However, additional actions within the brain and spinal cord may also contribute to the overall profile of the drug on sexual function. 9 As has been identified, sexual function comprises a complex series of interacting behavioural and physiological processes and dysfunctions can arise from minor perturbations at any one or more of several loci. The response to any drug is likely to be influenced by situational factors and highly dependent on the nature of the imbalance causing the ED. Furthermore the perception by the patient of clinical efficacy will be an individual one dependent on the sexual milieu, personal preference and the specific characteristics of the drug action (timeliness, tolerability, reliability, durability as well as efficacy). The patients set the goals of treatment 10 and these should be the major drivers in the determination of the drug of choice.
Central enhancement of erectile function was targeted for drug development because of the potential to reinforce normal central-peripheral pathways. Apomorphine had a suitable profile of action and a strong history of safe human use. The rationale for the development of the SL formulation of apomorphine, described elsewhere, 11 was to circumvent some of the shortcomings of existing therapy. In particular the route of administration and formulation were developed to ensure control and rapidity of onset and a greater separation of the optimal dose range for efficacy and the compliance limiting side effects of less sophisticated forms of administration.
The clinical trials programme for apomorphine SL has been conducted to explore the characteristics of this drug, which is the first exclusively centrally acting compound for use in ED. The apomorphine SL clinical programme was designed on classical (regulatory-based) lines using meaningful endpoints such as erections firm enough for intercourse, measured after each attempt and corroborated by partners. Although the challenges in designing the most appropriate clinical development programme for ED therapy are the subject of debate, it is pertinent to note, as discussed later, that the trial designs described in this article will potentially underestimate the 'real world' efficacy.
Methods
The data presented in this manuscript are a crossstudy analysis of responses for the approved 2 and 3 mg doses of apomorphine SL with particular attention to relevant subgroups and results as they impact on patients. One of the most important studies used in the compilation of this analysis is a crossover study 12 comparing 3 mg apomorphine SL with placebo and 3 mg with a higher than recommended dose (4 mg). Two hundred and seventy patients were enrolled in this study and inclusion and exclusion criteria are fully detailed elsewhere but were designed to replicate patients in the 'real world' or as seen by the community physician. 12 Further assessment of the overall benefit risk ratio and the overall durability of the response comes from additional data that have been analysed from the long-term studies 13 and from a dose optimisation study. 13 These studies are consistent in their methodology and primary endpoint and distinct from other series of studies on drugs for similar applications such as sildenafil. 14 Patients were asked to complete a diary for each tablet administration just after intercourse, and their partner completed a similar diary independently. Therefore all data have been compiled from diary records and record attempt by attempt results rather than generalised patient outcomes. The primary endpoint in all studies was the presence or absence of 'an erection firm enough for intercourse' in the view of the patient (and partner). Important secondary endpoints included per attempt data on actual intercourse and timing of response.
Results
In these studies men taking 3 mg of apomorphine SL experienced an improvement in their erections of between 1.7 and 3.2 times over their baseline function. For the study as a whole the number of attempts that resulted in an erection suitable for intercourse increased from 21% at baseline to 47% on 3 mg apomorphine SL. The placebo rate was 32% (n ¼ 163; P < 0.001 compared with placebo). The actual intercourse rate for the same study was 48% of all attempts by all patients, representing a substantial average 2.2-fold improvement over baseline (n ¼ 163; P < 0.001 compared with placebo). These improvements are seen consistently regardless of the pre-study aetiology, severity of the ED on inclusion (assessed by the International Index of Erectile Function (IIEF) or the presence of major comorbidity (coronary artery disease (CAD), hypertension (HT) or benign prostatic hyperplasia (BPH) (see Figure 1) .
The patients included in the study were classified according to baseline IIEF results. The severity of the ED of the patients included in the studies is given in the ED domain scores on the IIEF and is divided into mild (score 17 -22), moderate (score 11 -16) or severe (score < 10) based on recall over the prior 4 weeks. By way of reference, an approximate comparison can be made with the minimal moderate and complete criteria used in the Massachusetts Male Ageing Study (MMAS), 15 ( Figure 2 ).
In the apomorphine SL studies the severity of the ED in study patients has consistently been high and in this group 68% of patients have had moderate or severe degrees of ED. In the MMAS only 19% of the population studied had complete ED, 81% had mild to moderate ED. 15 The response of the study population has been examined after stratification by severity and the improvement over baseline that can be expected in each group has been shown in Figure 1 . Between 70 and 200% improvement can be seen in the three groups of men. Men with severe ED had baseline success of 11% of attempts successful that increased to 33% on apomorphine SL 3 mg (P ¼ 0.061 vs placebo). The moderate group had a baseline of 23% which improved to 55% on drug (P < 0.005 vs placebo) and the mild group improved from 38% to 66% (P < 0.005 vs placebo). This corresponds to an improvement from 31% to 60%, or a 94% improvement over baseline, in the number of attempts suitable for intercourse (P < 0.001 vs placebo) in the mild and moderate group combined.
Since the establishment of the aetiology of ED in an individual is subject to interpretation, and not yet standardised for the purposes of clinical trials, the patients were not categorised by aetiology. The diseases likely contributing to the ED (co-morbidities) can be documented and therefore the same population has been examined in sub-groups of men with relevant co-morbidities. The documentation of CAD was made when there was a history of coronary artery surgery (revascularisation), coronary angioplasty or treatment for angina; HT was diagnosed when the patient had a history of or active treatment for HT; BPH was diagnosed when the patient had received treatment for BPH. The results are summarised in Figure 1 . The patients with CAD have a lower baseline rate of erection but respond at a rate of 42% of attempts, while the patients with HT have a response rate of 44% compared with a baseline rate of 22% (P < 0.001 vs placebo) for an increase of 100%. Patients with BPH faired even better starting at a baseline rate of 18% that improved to 50% (P < 0.01 vs placebo) -a 178% improvement.
The IIEF can be scored in five domains: erectile function, 1 -30; orgasmic function, 0 -10; sexual desire, 2 -10; intercourse satisfaction, 0 -15; and overall satisfaction, 2 -10. Figure 3 shows how desire does not change while the erectile function domain score increases along with expected and related changes in satisfaction.
The time to erection was documented in the patient and partner diaries at each attempt. From these records it is possible to construct a cumulative plot and histogram of time to erection for those attempts resulting in erection -see Figure 4 . The data show that 34% of erections occurred within the first 10 min, a further 37% within the second 10 min giving a cumulative total of 71% of the erections within 20 min of taking the sublingual tablet. The pattern (frequency distribution) for placebo erections is similar but the erections recorded are fewer and more seldomly occur. Figure 2 The patients included in apomorphine SL study 12 stratified by the severity of the ED as determined at baseline. For comparison MMAS population data are included on the same scale. Figure 1 The improvement over baseline for the primary efficacy endpoint for 3 mg apomorphine on a per attempt basis (severity assessed by IIEF on enrolment, co-morbidities as present on enrolment, 13 ). All patients and all attempts have been included.
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Patients in clinical trials in ED are usually provided with an opportunity to enrol in long-term open label extensions of the short-term crossover trials. This long-term experience is primarily for assessing long-term safety but there are efficacy data that can be obtained as well. The rate at which patients transfer into these long-term phases is dependent on many factors as well as simple measures of efficacy. In the apomorphine SL trials about 82% of patients elected to enrol in long-term studies. The reliability of apomorphine SL in maintaining efficacy over long-term use is shown graphically in Figures 5 and 6 . These data show that even at 2 mg patients experiencing a response will continue to demonstrate that response in over 90% of attempts.
In all patient populations the incidence of side effects reported for the 2 and 3 mg doses of apomorphine SL compared with placebo were remarkably low. Only nausea (6.8% at 2 and 3 mg) and headache (6.7% of patients at 2 and 3 mg) reached greater than 5% incidence. These are described in detail elsewhere. 16 
Discussion
The precise methodology for the stratification of ED into mild, moderate and severe has been the subject Figure 5 The reliability (percentage of attempts successful in producing an erection suitable for intercourse) of apomorphine SL 2 mg taken over 6 months. Data for patients on 2 mg at 6 months (n ¼ 55, composite data). of considerable debate and some degree of controversy. However, it is pertinent to note that the clinical benefit of apomorphine is similar across all 'severities' defined from the IIEF scores at baseline. The profiles of patients participating in these studies include more severe patients than in the MMAS. 15 Furthermore patients were required to attempt intercourse at least twice a week in the crossover studies. This may represent an unnaturally high frequency compared to the 'real world' sexual activity of men in their 50s with ED. On this basis, it is extremely likely that the clinical trials design mandated by the regulatory authorities will result in an underestimate of the actual responder rate to apomorphine SL in the community setting. Even with this caveat, reassuringly, from both the patient and physician perspective, not only does the response to apomorphine SL appear predictable but also it is durable. In patients responding to apomorphine SL, over 90% of attempts are successful over 6, 12 or 18 months. Should this translate to clinical use in the community this would represent a remarkably high compliance rate for adopting patients not only by the standards of an agent for ED but for most other disease areas.
It is important to note that the degree of response in both short and long term studies seems relatively unaffected by the common and relevant co-morbidities found in the ED patients, particularly HT, CAD, diabetes and BPH.
Throughout the apomorphine SL clinical programme a relevant primary endpoint 'erection firm enough for intercourse' -one that has meaning for the patient and partner was used. It is recognised that no single measure of efficacy can mirror the complex variety of issues that are inherent in the satisfaction of an individual, or couple, with their sexual experience. More likely the attribution of satisfaction is a complex amalgam of rigidity, speed of onset, spontaneity, reliability, tolerability, partner responses and more. Preference for a treated state vs an untreated state should be a given in such studies and efficacy in the complex environment of sexual function should remain an individual preference. The efficacy was evaluated, and found to be reproducible, in the treatment of ED patients across a wide range of aetiologies and with the comorbidities normally manifest in the ED patient.
Based on these extensive clinical evaluations, it can be concluded that the consistency and durability of response to apomorphine will be well received by ED patients across a broad spectrum of aetiologies and severities. Coupled with the relatively benign side effect profile and particularly the rapidity of onset, permitting spontaneity, as well as long-term consistency of response, many patients may well express a preference for the overall profile that apomorphine SL could offer them.
